Marc Frahm
Stock Analyst at TD Cowen
(0.33)
# 4,422
Out of 5,182 analysts
16
Total ratings
23.08%
Success rate
-17.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Hold | $13 → $15 | $16.76 | -10.50% | 4 | Mar 23, 2026 | |
| NKTR Nektar Therapeutics | Initiates: Buy | n/a | $83.81 | - | 1 | Mar 17, 2026 | |
| INCY Incyte | Maintains: Buy | $101 → $128 | $97.74 | +30.96% | 4 | Jan 13, 2026 | |
| SANA Sana Biotechnology | Upgrades: Buy | n/a | $3.35 | - | 2 | Jan 8, 2025 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $12.81 | - | 1 | Jun 15, 2023 | |
| XLO Xilio Therapeutics | Initiates: Outperform | n/a | $7.88 | - | 1 | Nov 16, 2021 | |
| NUVL Nuvalent | Initiates: Outperform | n/a | $101.94 | - | 1 | Aug 23, 2021 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $14.50 | - | 1 | Jul 6, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | n/a | $2.70 | - | 1 | Feb 24, 2020 |
Theravance Biopharma
Mar 23, 2026
Maintains: Hold
Price Target: $13 → $15
Current: $16.76
Upside: -10.50%
Nektar Therapeutics
Mar 17, 2026
Initiates: Buy
Price Target: n/a
Current: $83.81
Upside: -
Incyte
Jan 13, 2026
Maintains: Buy
Price Target: $101 → $128
Current: $97.74
Upside: +30.96%
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $3.35
Upside: -
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.81
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.88
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $101.94
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.50
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.70
Upside: -